Intelligent Blood Sequestration System for Real-Time Microbial Infection Detection and Personalized Treatment

A next-generation blood sequestration device integrating microfluidic, biosensor, data analytics, and artificial intelligence technologies to enable real-time microbial infection detection, personalized treatment, and remote monitoring, revolutionizing blood culture analysis and patient care.

The original blood sequestration device patent ( Blood sequestration device and method ) addressed the need for safe and efficient blood sampling. However, it lacked the capability to detect microbial infections in real-time, relied on manual analysis, and did not provide personalized treatment recommendations. The new inventive concept addresses these limitations by incorporating advanced technologies to provide a more comprehensive and efficient solution.

The intelligent blood sequestration system consists of a microfluidic module for real-time microbial infection detection, a biosensor for detecting biomarkers, a data analytics module for predicting patient outcomes and suggesting personalized treatment regimens, and an artificial intelligence module for adapting to changing patient conditions and optimizing blood culture analysis. The system can be integrated with a cloud-based platform and mobile application for remote monitoring and real-time updates.

The new inventive concept's integration of microfluidic, biosensor, data analytics, and artificial intelligence technologies enables real-time microbial infection detection, personalized treatment, and remote monitoring, which is not taught by the original patent. The incorporation of these advanced technologies provides a novel and non-obvious solution that significantly improves blood culture analysis and patient care.

Alternative embodiments of the inventive concept could include the use of different biosensor technologies, such as nano-particle based sensors or graphene-based sensors, or the integration of genomic analysis for personalized medicine. Variations could also include the development of a handheld device for point-of-care testing or a decentralized system for remote monitoring and analysis.

The intelligent blood sequestration system has significant commercial potential in the healthcare industry, particularly in the areas of infectious disease diagnosis and personalized medicine. The system could be marketed to hospitals, clinics, and research institutions, and could also be used in decentralized healthcare settings, such as telemedicine platforms and remote patient monitoring services.